Introduction {#Sec1}
============

According to MODOMICS, 163 different chemical modifications in RNA have been identified in all living organisms by the end of 2017 \[[@CR1]\]. Among these modifications, N^6^-methyladenosine (m^6^A), methylated at the N^6^ position of adenosine, has been considered as the most pervasive, abundant and conserved internal transcriptional modification within eukaryotic messenger RNAs (mRNAs) \[[@CR2]\], microRNAs (miRNAs) \[[@CR3]\] and long non-coding RNAs (lncRNAs) \[[@CR4]\]. RNA m^6^A is enriched near stop codon and 3′ untranslated terminal region (UTR) \[[@CR5], [@CR6]\] and translated near 5′ UTR in a cap-independent manner \[[@CR7]\], thereby affecting RNA transcription, processing, translation and metabolism.

The deposition of m^6^A is encoded by a methyltransferase complex involving three homologous factors jargonized as 'writers', 'erasers' and 'readers' (Fig. [1](#Fig1){ref-type="fig"}). Methyltransferase-like 3 (METTL3) \[[@CR8]\], METTL14 \[[@CR9]\], Wilms tumor 1-associated protein (WTAP) \[[@CR10]\], RBM15/15B \[[@CR11]\] and KIAA1429 \[[@CR12]\] are categorized as the components of 'writers' that catalyze the formation of m^6^A; 'erasers', fat mass and obesity-associated protein (FTO) \[[@CR13]\] and alkB homologue 5 (ALKBH5) \[[@CR14]\], selectively remove the methyl code from target mRNAs; 'Readers' are capable of decoding m^6^A methylation and generating a functional signal, including YT521-B homology (YTH) domain-containing protein \[[@CR15]\], eukaryotic initiation factor (eIF) 3 \[[@CR11]\], IGF2 mRNA binding proteins (IGF2BP) families \[[@CR16]\] and heterogeneous nuclear ribonucleoprotein (HNRNP) protein families \[[@CR17]\]. YTH domain can recognize m^6^A through a conserved aromatic cage \[[@CR18]\] and another two proteins FMR1, LRPPRC "read" this modification \[[@CR19], [@CR20]\]. Contrary to the conventional 'writer'-'eraser'-'reader' paradigm, few studies reveal METTL3/16 as a m^6^A 'writer' or 'reader' \[[@CR21]\].Fig. 1Molecular composition of m^6^A RNA methylation. M^6^A methylation is a dynamic and reversible process coordinated by a series of methyltransferases (METTL3/14, WTAP, RBM15/15B, and KIAA1429, termed as "m^6^A writers"), demethylases (FTO and ALKBH5, "m^6^A erasers") and identifiers (YTHDF1/2/3, YTHDC1, HNRNPA2B1, HNRNPC, eIF3, FMR1, and LRPPRC, "m^6^A. 'Readers")

M^6^A RNA modification is a dynamic and reversible process which was corroborated by the discovery of 'eraser' in 2011 \[[@CR13]\]. It is associated with multiple diseases such as obesity, infertility and cancer \[[@CR22]\]. In this review, we summarize the function and therapeutic advances of m^6^A modifications in human cancer and provide their promising applications in the treatment of these malignant tumors (Table [1](#Tab1){ref-type="table"}).Table 1Multiple functions exerted by m^6^A RNA methylation in various diseasesDiseaseRelated targetsM^6^A componentFunctionRole in diseasesSource of experimental evidenceRegulationYearRefsAMLc-MYC, BCL2, PTENMETTL3WritersoncogeneHSPCs, AML MOLM-13 cellsUp-regulation2017\[[@CR70]\]AMLCEBPZMETTL3WritersoncogeneAML cells, immunodeficient miceUp-regulation2017\[[@CR23]\]AMLMYB, MYCMETTL14WritersoncogeneAML cell linesUp-regulation2017\[[@CR68]\]AMLmTORWTAPWritersoncogene511 newly diagnosed AML patient samples, Ba/F3 cell line, AML cell linesDown-regulation2014\[[@CR69]\]AMLASB2, RARAFTOErasersoncogeneMONOMAC-6 and NB4 cellsDown-regulation2017\[[@CR67]\]AMLMYC, CEBPAFTOErasersoncogene27 human leukemia cell linesUp-regulation2018\[[@CR24]\]AMLTal1...YTHDF2Readersanti- oncogeneHSPCs, mouse...Down-regulation2018\[[@CR72]\]Bladder cancerAFF4, MYCMETTL3WritersoncogeneBladder cancer cell lines, mouse bladder cancer samplesUp-regulation2019\[[@CR44]\]Breast cancerHBXIPMETTL3Writersoncogene24 clinical tumor samples, MCF-7, MDA-MB-468 cellsUp-regulation2018\[[@CR78]\]Breast cancerNANOGALKBH5ErasersoncogeneBCSCsUp-regulation2016\[[@CR79]\]CRCWT1, TBL1WTAPWritersoncogene115 patient samples with CRC, colon cancer cell linesDown-regulation2016\[[@CR81]\]Endometrial cancerAKT...METTL3/14Writersanti- oncogeneCancer samples, endometrial cancer cell lines, miceDown-regulation2018\[[@CR66]\]GBMADAM19METTL3/14Writersanti- oncogeneGSC, GSC-grafted miceDown-regulation2017\[[@CR74]\]GBMFOXM1ALKBH5ErasersoncogeneGSCsUp-regulation2017\[[@CR73]\]HCCSOCS2METTL3WritersoncogeneMHCC97L, Huh-7 and HepG2 cell lines, BABL/cAnN-nude miceDown-regulation2017\[[@CR37]\]HCCmiR-126METTL14Writersanti-oncogeneHepG2 cellUp-regulation2017\[[@CR26]\]HCCmiR-145YTHDF2Readersoncogeneclinical tissue, HepG2 cell linemiR-145 suppresses YTHDF22017\[[@CR77]\]HCC, AML...SRF...IGF2BP1ReadersoncogeneHepG2, K562, hESCs cell lines...Up-regulation2019\[[@CR16]\]impaired fertilityUhrf1...ALKBH5ErasersspermatogenesisHeLa cells, mouse testicular cellsUp-regulation2013\[[@CR14]\]Lung cancerEGFR, TAZMETTL3WritersoncogeneHuman lung cancer cell lines, HeLa, HEK293T cellsUp-regulation2016\[[@CR46]\]NPCZNF750, FGF14METTL3WritersoncogeneNPC biopsy samples and cell linesDown-regulation2018\[[@CR45]\]ObesitySRSF2FTOErasersadipogenesis3 T3-L1 cellDecreased RNA binding ability2014\[[@CR28]\]Pancreatic cancerRBM17...METTL3WritersoncogenePancreatic cancer cell linesUp-regulation2018\[[@CR31]\]*HSPCs* hematopoietic stem/progenitor cells, *AML* acute myeloid leukemia, *GBM* Glioblastoma, *GSC* glioblastoma stem cell, *HCC* hepatocellular cancer, *CRC* colorectal cancer, *BCSCs* Breast cancer stem cells, *NPC* Nasopharyngeal carcinoma

Biological function of m^6^A modification in mammals {#Sec2}
----------------------------------------------------

Recent years have witnessed a substantial progress of m^6^A post-transcriptional modification in regulating RNA transcription \[[@CR23], [@CR24]\], processing event \[[@CR25]--[@CR27]\], splicing \[[@CR28]--[@CR33]\], RNA stabilities \[[@CR34]--[@CR40]\] and translation \[[@CR42]--[@CR49]\] (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Regulatory Functions of m^6^A modification in RNA splicing, processing, translation and degradation. M^6^A RNA modification is involved in regulating the life cycle of RNA including RNA splicing (regulated by WTAP, FTO, ALKBH5 and YTHDC1), RNA processing (regulated by METTL3/14 and ALKBH5), RNA translation (regulated by METTL3, YTHDF1/3, eIF3 and FMR1) and RNA degradation (regulated by YTHDF2)

### M^6^A modification in RNA transcript {#Sec3}

METTL3 and FTO are implicated in regulating transcription of CCAAT-enhancer binding protein (CEBP) family. METTL3 is localized to the starting sites of CEBPZ, which is required for recruitment of METTL3 to chromatin \[[@CR23]\]. CEBPA is identified as an exclusive transcription factor displaying a positive correlation with FTO and regulating its transcription in acute myeloid leukemia (AML) \[[@CR24]\].

### M^6^A modification in RNA processing {#Sec4}

M^6^A modifications promote the initiation of miRNA biogenesis \[[@CR3]\] and regulate nuclear mRNA processing events \[[@CR25]\]. METTL3 recognizes the pri-miRNAs by microprocessor protein DGCR8 and causes the elevation of mature miRNAs and concomitant reduction of unprocessed pri-miRNAs in breast cancer \[[@CR3]\]. METTL14 interacts with DGCR8 to modulate pri-miR-126 and suppresses the metastatic potential of hepatocellular carcinoma (HCC) \[[@CR26]\]. FTO can regulate poly(A) site and 3′ UTR length by interacting with METTL3 \[[@CR25]\]. YTHDC1 knockout in oocytes exhibits massive defects and contributes to extensive alternative polyadenylation and 3′ UTR length alterations \[[@CR27]\].

### M^6^A modification in RNA splicing {#Sec5}

M^6^A RNA modifications that overlap in space with the splicing enhancer regions affect alternative RNA splicing by acting as key pre-mRNA splicing regulators \[[@CR28]\]. Inhibiton of m^6^A methyltransferase impacts gene expression and alternative splicing patterns \[[@CR29]\]. FTO regulates nuclear mRNA alternative splicing by binding with SRSF2 \[[@CR25]\]. FTO and ALKBH5 regulate m^6^A around splice sites to control the splicing of Runt-related transcription factor 1 (RUNX1T1) in exon \[[@CR28]\], and removal of m^6^A by FTO reduces the recruitment of SRSF2 and prompts the skipping of exon 6, leading to a short isoform of RUNX1T1 \[[@CR30]\]. Depletion of METTL3 is associated with RNA splicing in pancreatic cancer \[[@CR31]\]. WTAP is enriched in some proteins involved in pre-mRNA splicing \[[@CR32]\]. But, some studies show that, M^6^A is not enriched at the ends of alternatively spliced exons and METTL3 unaffects pre-mRNA splicing in embryonic stem cells \[[@CR33]\].

### M^6^A modification in RNA degradation {#Sec6}

M^6^A is a determinant of cytoplasmic mRNA stability \[[@CR34]\], and reduces mRNA stability \[[@CR35]\]. A RNA decay monitoring system is adopted to investigate the effects of m^6^A modifications on RNA degradation \[[@CR36]\]. Knockdown of METTL3 abolishes SOCS2 m^6^A modification and augments SOCS2 expression \[[@CR37]\]. M^6^A-mediated SOCS2 degradation also relies on m^6^A 'reader' YTHDFs \[[@CR37]\], which accelerate the decay of m^6^A-modified transcripts \[[@CR38]\] or target mRNA \[[@CR39]\]. Knockout of m^6^A methyltransferase attenuates YTHDF2 specific binding with target mRNAs and increases their stability \[[@CR40]\]. M^6^A RNA methylation also controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways \[[@CR41]\] and decreases the stability of MYC/CEBPA transcripts \[[@CR24]\].

### M^6^A modification in RNA translation {#Sec7}

M^6^A modifications occur in mRNA and noncoding RNA (ncRNAs) to regulate gene expression in its 5′ or 3′ UTR \[[@CR7], [@CR42]\]. METTL3 enhances mRNA translation \[[@CR8]\], while depletion of METTL3 selectively inhibits mRNAs translation in 5′UTR \[[@CR43]\] and reduces AFF4 and MYC translation in bladder cancer \[[@CR44]\] but increase that of zinc finger protein 750 and fibroblast growth factor 14 in nasopharyngeal carcinoma \[[@CR45]\].

M^6^A modifications facilitate the initiated translation through interacting with the initiation factors eIF3, CBP80 and eIF4E in an RNA-independent manner \[[@CR46]\]. Heat-shock-induced translation of heat-shock protein 70 (HSP70) alters the transcriptome-wide distribution of m^6^A \[[@CR7]\] and affects DNA repair \[[@CR47]\]. ABCF1-sensitive transcripts largely overlaps with METTL3-modified mRNAs and are critical for m^6^A-regulated mRNA translation \[[@CR43]\]. In addition, FMR1 binds to hundreds of mRNAs to negatively regulate their translation \[[@CR20]\]. YTHDF1 facilitates the translation of m^6^A-modified mRNAs in protein-synthesis and YTHDF3 acts in the initial stage of m^6^A-driven translation from circular RNAs (circRNAs) \[[@CR38], [@CR48], [@CR49]\].

M^6^A RNA modification in metabolic and developmental diseases {#Sec8}
--------------------------------------------------------------

The methyltransferases and demethylases of m^6^A are associated with a variety of diseases, such as obesity \[[@CR13], [@CR50]\], type 2 diabetes mellitus (T~2~DM) \[[@CR51]\], growth retardation, developmental delay, facial dysmorphism \[[@CR52]\]. Besides, m^6^A modification affects infertility \[[@CR14]\], developmental arrest \[[@CR22]\], neuronal disorder \[[@CR53]\] and infectious diseases \[[@CR54], [@CR55]\].

### M^6^A modification in metabolic and infectious diseases {#Sec9}

M^6^A modification is involved in metabolic abnormalities in patients with T~2~DM and obesity \[[@CR56]\]. FTO regulates the energy homeostasis and dopaminergic pathway through FTO-dependent m^6^A demethylation \[[@CR50], [@CR51]\], and it is ubiquitous in adipose and muscle tissues, influencing RUNX1T1 splicing in adipogenesis \[[@CR28], [@CR30]\]. METTL3/14 reduce the abundance of Hepatitis C virus replication, but FTO promotes its production through YTHDF proteins \[[@CR54]\]. M^6^A is also identified as a conserved modulatory symbol across Flaviviridae genomes, including dengue, Zika virus and West Nile virus \[[@CR55]\].

### M^6^A modification in infertility {#Sec10}

Deficiency of demethylase ALKBH5 leads to the aberrant spermatogenesis and apoptosis with impaired fertility in testes and striking changes in DNA methyltransferase 1 (Dnmt1) and ubiquitin-like with PHD and RING finger domains 1 (Uhrf1) \[[@CR14]\]. YTHDF2 is required for maternal transcriptome during oocyte maturation \[[@CR57]\]. YTHDC1/2 determine the germline development in mouse \[[@CR58]\], and YTHDC1 is essential for spermatogonia in males and oocyte maturation in females \[[@CR27]\].

### M^6^A modification in nervous system development {#Sec11}

M^6^A modification regulates the pace of cerebral cortex development \[[@CR59]\] and m^6^A-regulated histone modifications enhances self-renewal of neural stem cells by METTL3/14 \[[@CR60]\]. M^6^A has dual effects on delaying tempo of corticogenesis by two distinct pathways: increased cell-cycle length and decreased mRNA decay \[[@CR59]\]. M^6^A depletion decreases the decay of radial glia cells associated with stem cell maintenance, neurogenesis and differentiation \[[@CR61]\].

### M^6^A modification in inflammation and metabolism-related cancer {#Sec12}

Cacinogenesis is characterized by stepwise accumulation of genetic/epigenetic alterations of different proto-oncogenes and tumor-suppressor genes following other diseases including chronic inflammation and metabolic diseases. METTL3/14 and FTO influence Hepatitis C virus replication and production, and endogenous mediators of inflammatory responses (proinflammatory cytokines, reactive oxygen, et al) can promote genetic/epigenetic alterations \[[@CR62]\]. FTO affects RUNX1T1 splicing in adipogenesis \[[@CR28], [@CR30]\], and RUNX1T1 is essential for pancreas development \[[@CR63]\]. Transcription factor forkhead box protein O1 (FOXO1) as another direct substrate of FTO, regulates gluconeogenesis in liver \[[@CR64]\] and promotes the growth of pancreatic ductal adenocarcinoma \[[@CR65]\].

M^6^A RNA modification in human cancer {#Sec13}
--------------------------------------

Emerging evidence suggests that, m^6^A modification is associated with the tumor proliferation, differentiation, tumorigenesis \[[@CR46]\], proliferation \[[@CR66]\], invasion \[[@CR46]\] and metastasis \[[@CR26]\] and functions as oncogenes or anti-oncogenes in malignant tumors (Table [1](#Tab1){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}).Fig. 3The role of m^6^A RNA modification in human cancer. M^6^A RNA modification is associated with the tumorigenesis of multiple malignancies including AML, GBM, HCC, CRC, NPC, breast cancer, lung cancer, pancreatic cancer, bladder cancer and endometrial cancer

### Acute myeloid leukemia (AML) {#Sec14}

FTO is highly expressed in AML with t(11q23)/MLL rearrangements, t(15;17)/PML-RARA, FLT3-ITD and/or NPM1 mutations and promotes leukemic cell transformation and tumorigenesis \[[@CR67]\]. METTL3/14 are expressed in hematopoietic stem/progenitor cells (HSPCs) and AML cells with t(11q23), t(15;17), or t(8;21), control the terminal myeloid differentiation of HSPCs and promote the survival and proliferation of AML \[[@CR68]\]. WTAP acts in cell proliferation and arrests the differentiation of leukemia \[[@CR69]\].

M^6^A promotes the translation of *c-MYC*, *BCL2* and *PTEN* in AML \[[@CR70]\]. METTL14 acts an oncogenic role by regulating its targets MYB/MYC through m^6^A modification \[[@CR68]\]. YTHDF2, responsible for the decay of m^6^A-modified mRNA transcripts \[[@CR40]\], is also associated with MYC in leukemia \[[@CR71]\]. Besides, YTHDF2 stabilizes Tal1 mRNAs and increases its expansion in AML \[[@CR72]\].

Collectively, these studies corroborate the functional importance of m^6^A modifications in leukemia, such as METTL3 \[[@CR23], [@CR70]\], METTL14 \[[@CR68]\], FTO \[[@CR24], [@CR67]\] and YTHDF2 \[[@CR24], [@CR40]\] and they provide profound insights into development and maintenance of AML and self-renewal of leukemia stem/initiation cells through the downstream MYC and Tal1 pathways.

### Glioblastoma (GBM) {#Sec15}

METTL3/14 inhibit GSC growth, self-renewal and tumorigenesis, but FTO and ALKBH5 indicate poor survival in GBM by regulating ADAM19 and transcription factor FOXM1 \[[@CR73], [@CR74]\]. LncRNA antisense to FOXM1 (FOXM1-AS) promotes the interaction of ALKBH5 with FOXM1 nascent transcripts in the tumorigenesis of GSCs \[[@CR73]\].

### Lung cancer {#Sec16}

M^6^A demethylase FTO is identified as a prognostic factor in lung squamous cell carcinoma (LUSC) and facilitates cell proliferation and invasion, but inhibits cell apoptosis by regulating MZF1 expression \[[@CR75]\]. METTL3 acts as a oncogene in lung cancer by increasing EGFR and TAZ expression and promoting cell growth, survival and invasion \[[@CR46]\]. METTL3-eIF3 caused mRNA circularization promotes the translation and oncogenesis of lung adenocarcinoma \[[@CR46]\]. Besides, SUMOylation of METTL3 is of importance for the promotion of tumor growth at lysine residues K^177^, K^211^, K^212^ and K^215^ in non-small cell lung carcinoma (NSCLC) \[[@CR76]\]. These studies provide insights into the critical roles of METTL3 and FTO in lung carcinoma.

### Hepatocellular carcinoma (HCC) {#Sec17}

METTL3 is related to a poor prognosis in HCC patients and promotes HCC cell proliferation, migration and colony formation by YTHDF2-dependent posttranscriptional silencing of SOCS2 \[[@CR37]\]. But, METTL14 is an anti-metastatic factor and serves as a favorable factor in HCC by regulating m^6^A-dependent miRNA processing \[[@CR26]\]. MiR-145 down-regulates YTHDF2 through targeting its mRNA 3′ UTR \[[@CR77]\]. In conclusion, METTL3 upregulation or METTL14 downregulation predicts poor prognosis in patients with HCC and contributes to HCC progression and metastasis \[[@CR26], [@CR37]\]. METTL3 suppresses SOCS2 expression in HCC via the miR-145/m^6^A/YTHDF2 dependent axis \[[@CR37], [@CR77]\]. Thus, these studies suggest a new dimension of epigenetic alteration in liver carcinogenesis.

### Breast cancer and colorectal cancer (CRC) {#Sec18}

METTL3 is associated with the expression of mammalian hepatitis B X-interacting protein (HBXIP), displaying an aggressiveness in breast cancer. HBXIP-induced METTL3 promotes the proliferation of breast cancer via inhibiting tumor suppressor let-7 g \[[@CR78]\]. Besides, ALKBH5 decreases the levels of m^6^A in NANOG mRNA and enhances its stability, leading to an increase of NANOG mRNA and protein levels in breast cancer stem cells (BCSCs) \[[@CR79]\]. Another m^6^A eraser 'FTO' polymorphism has no association with the risk of CRC \[[@CR80]\], but the m^6^A 'writer' WTAP is associated with carbonic anhydrase IV (CA4), which inhibits the proliferation and induces apoptosis and cycle arrest by repressing the Wnt signaling through targeting the WTAP-WT1-TBL1 axis \[[@CR81]\].

### Brief summary of m^6^A modification-related carcinogenesis {#Sec19}

M^6^A RNA modifications regulate RNA production/metabolism and take part in the carcinogenesis. On the one hand, m^6^A-modified genes usually act a oncogenic role in cancer, leading to alterations of mRNA translation and acceleration of tumor progression, and decreasing m^6^A modification results in tumor development. On the other hand, given that SUMOylation of METTL3 represses its m^6^A methyltransferase capacity and results in tumor growth of NSCLC, modification of m^6^A methylase can determine the tumor development.

### M^6^A modification in cancer treatment {#Sec20}

M^6^A modification indicates new directions for the treatment of various cancers. Regulators or inhibitors of m^6^A modifications may provide the potential therapeutic strategies for cancers, such as MA2 in GBM \[[@CR74]\], R-2HG/SPI1/FB23--2 in AML \[[@CR24], [@CR68], [@CR82]\] and CA4 in CRC \[[@CR81]\]. Meclofenamic acid (MA) as one of the selective FTO inhibitors is a non-steroidal anti-inflammatory drug by competing with FTO binding sites \[[@CR83]\]. MA2, the ethyl ester derivative of MA, increases m^6^A modification, leading to the suppression of tumor progression \[[@CR74], [@CR83]\]. The expression of ASB2 and RARA is increased in hematopoiesis and they act as key regulators of ATRA-induced differentiation of leukemia cells \[[@CR84]\]. FTO enhances the leukemogenesis of AML by inhibition of the ASB2 and RARA expression \[[@CR67]\]. FB23--2, as another inhibitor of m^6^A demethylase FTO suppresses AML cell proliferation and promotes the cell differentiation and apoptosis \[[@CR82]\].

ALKBH5 and FTO are α-ketoglutarate (α-KG)-dependent dioxygenases \[[@CR85]\], which are competitively inhibited by D2-hydorxyglutarate (D2-HG) and elevated in isocitrate de-hydrogenases (IDH)-mutant cancers for transferring isocitrate to α-KG \[[@CR86]\]. R-2-hydroxyglutarate (R-2HG), an metabolite by mutating IDH1/2 enzyme, exhibits anti-leukemia effects through increasing m^6^A levels in R-2HG-sensitive AML \[[@CR24]\].

S-adenosylmethionine (SAM) serves as a cofactor substrate in METTL3/14 complex and its product S-adenosylhomocysteine (SAH) inhibits the methyltransferases by competing with adenosylmethionine \[[@CR87]\]. 3-deazaadenosine (DAA) inhibits SAH hydrolase and interrupts insertion of m^6^A into mRNA substrates \[[@CR88]\] and its analogs suppress the replication of various viruses editing m^6^A- mRNA in cancers \[[@CR89], [@CR90]\].

METTL14 acts an oncogenic role by regulating MYB/MYC axis through m^6^A modification \[[@CR68]\]. SPI1, a hematopoietic transcription factor, directly inhibits METTL14 expression in malignant hematopoietic cells \[[@CR68]\] and may be a potential therapeutic target for AML. CA4 inhibits the tumorigenicity of CRC by suppressing the WTAP-WT1-TBL1 axis \[[@CR81]\].

### Future prospect {#Sec21}

M^6^A RNA modifications act by regulating RNA transcript, splicing, processing, translation and decay and participate in the tumorigenesis and metastasis of multiple malignancies. However, the underlying mechanisms of m^6^A modifications in cancer should be further addressed.. Besides FMR1 and LRPPRC, the function of ALKBH family in m^6^A RNA methylation is undetermined. METTL14 has different expression levels in various tumor tissues. Given a dual role of METTL14 either as a tumor suppressor \[[@CR26]\] or an oncogene in cancer \[[@CR68]\], its role in other cancers need be further elucidated. Though some inhibitors of m^6^A methylation have shown promising effects on cancer development \[[@CR68], [@CR81]\], novel therapeutic strategies for m^6^A RNA methylation should be further explored in the treatment of cancer.
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